 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zymeworks Inc. ( Zymeworks...

ZYMEWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Zymeworks Inc. on Behalf of Zymeworks Stockholders and Encourages Investors to Contact the Firm

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zymeworks Inc. ( Zymeworks or the Company ) (NASDAQ: ZYME). The...

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)

This price move could be a signal that ZYME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

Zymeworks (ZYME, $9.86) price may climb as it broke lower Bollinger Band on Apr 01, 2024

For the last three days, A.I.dvisor has detected that ZYME's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Zymeworks (ZYME, $9.86) Aroon Indicator entered a Downtrend on April 01, 2024.

This is a signal that ZYME's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Zymeworks (ZYME, $9.86) RSI Indicator left the oversold zone on April 01, 2024

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ( Zymeworks or the Company ) (NASDAQ: ZYME). Such investors are advised...

Zymeworks (ZYME, $10.5) Aroon Indicator entered a Downtrend on March 28, 2024.

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Volume (M)	1M
52-Wk High	$13.14
52-Wk Low	$6.02

ZYME Zymeworks Inc

About

Feed

News

Sentiment

Earnings

Fundamentals